Helix BioPharma (TSE:HBP) Shares Pass Above 50 Day Moving Average – Time to Sell?

Helix BioPharma Corp. (TSE:HBP)’s stock price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$1.47 and traded as high as C$1.48. Helix BioPharma shares last traded at C$1.48, with a volume of 416 shares traded.

Helix BioPharma Stock Down 1.3%

The business has a 50 day moving average of C$1.47 and a 200 day moving average of C$1.74. The company has a debt-to-equity ratio of 2.44, a current ratio of 0.45 and a quick ratio of 1.03. The firm has a market capitalization of C$113.04 million, a price-to-earnings ratio of -37.00 and a beta of 0.43.

Helix BioPharma (TSE:HBP) last posted its quarterly earnings results on Friday, June 12th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. On average, equities analysts anticipate that Helix BioPharma Corp. will post -0.11 EPS for the current year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.